The loss or mutation of the VHL gene is found in 60–90% ccRCC cases, prompting the use of agents targeting circulating VEGF and VEGF receptors for ccRCC treatment [1]. The gene discussed is VHL; the disease is nonpapillary renal cell carcinoma.